Latest findings on rheumatological drug therapies, including methotrexate for RA, tumor necrosis factor inhibitors for SpA
Lupus Classification Criteria Expanded; Treat-to-Target Approach Gains Support
Rheumatologists at the California Rheumatology Alliance 10th Annual Medical & Scientific Meeting in San Francisco outline disease classification criteria, treat-to-target approach to lupus
Rheumatologist Marc C. Hochberg, MD, MPH, Advances Epidemiology Through Collaborative Ties
Accomplished physician noted for research in gout, osteoarthritis etiology; characterizing therapeutic responsiveness in disease states; inspiring teamwork among rheumatologists
MicroRNA-Based Therapeutics Hold Promise Against Lupus, Other Rheumatic Diseases Note Experts at the ACR/ARHP’s 2013 Annual Meeting
Studies suggest deregulation, dysfunction of miRNAs in human, mice models of lupus may be future targets for gene therapy
Tips for Treating Pain, Depression in Patients with Rheumatic Disease Offered at the ACR/ARHP’s 2013 Annual Meeting
Observational pain scales, diagnostic tools, pharmacologic interventions, and support from psychologists, caregivers recommended
Global Perspectives on Managing Rheumatoid Arthritis Addressed at the 2013 ACR/ARHP Annual Meeting
Poverty, poor access to healthcare, cultural myths present challenges for rheumatologists caring for patients with RA in developing economic regions
Therapeutic Value of Colchicine in Osteoarthritis, Cardiovascular Disease Explored at the ACR/ARHP Winter Rheumatology Symposium
Drug’s antiinflammatory properties may help alleviate pain in patients with OA, reduce risk of myocardial infarction, but toxicity, drug interactions need to be considered
Treatment Options, Guidelines for Managing Gout Discussed at the ACR/ARHP Winter Rheumatology Symposium
Better understanding of goals, effect of gout therapy with nonsteroidal anti-inflammatory drugs, urate lowering medication needed to improve quality of care
Treating Early-Stage Spondyloarthritis May Prevent Disease Progression, Say Researchers at the ACR/ARHP Winter Rheumatology Symposium
Therapy with tumor necrosis factor inhibitors, nonsteroidal antiinflammatory drugs, ustekinumab in early stages of osteitis may halt molecular switching to bone-forming phenotype characteristic of SpA
Methotrexate May Mitigate Inflammatory Bone Disease Note Experts at the ACR/ARHP Winter Rheumatology Symposium
By regulating molecules key to osteoclast/osteoblast processes, methotrexate may reduce bone destruction in inflammatory arthritis, osteolysis, especially in combination with adenosine
- « Previous Page
- 1
- …
- 80
- 81
- 82
- 83
- 84
- …
- 97
- Next Page »